This trial is active, not recruiting.

Conditions critical illness, acute respiratory failure
Treatment olimel (5.7%e / n9e)
Phase phase 3
Sponsor Clinical Evaluation Research Unit at Kingston General Hospital
Collaborator Baxter Healthcare Corporation
Start date June 2011
End date July 2015
Trial size 160 participants
Trial identifier NCT01206166, TOP-UP


The specific aim of the proposed study is to conduct a pilot study involving 160 critically-ill lean and obese patients enrolled at 11 sites in Canada, the United States of America, Belgium and France in order to:

Specific Aims

- Confirm that we can achieve a clinically significant difference in calorie and protein intake between the two intervention groups.

- Estimate recruitment rate i.e. number of eligible and enrolled patients per month per site.

- Evaluate the safety, tolerance, and logistics around providing supplemental PN in the study population in the context of a multicenter trial, e.g.

- To ensure adequate glycemic control in both groups.

- To ensure that the other metabolic consequences of the feeding strategies are minimized.

- To establish adequate compliance with study protocols and completion of case report forms

A secondary aim of this pilot study will be:

• To explore the effect of differential effects of calorie and protein delivery on muscle and mass function.

United States No locations recruiting
Other countries No locations recruiting

Study Design

Allocation randomized
Endpoint classification safety/efficacy study
Intervention model parallel assignment
Masking open label
Primary purpose prevention
Enteral nutrition with the addition of parenteral supplementation (Olimel 5.7%E/N9E).
olimel (5.7%e / n9e) Olimel
OLIMEL(Amino Acids, Dextrose, Lipids, with / without Electrolytes) is indicated for parenteral nutrition for adults when oral or enteral nutrition is impossible, insufficient or contraindicated.
(No Intervention)
Enteral nutrition only - no intervention

Primary Outcomes

Amount of calories and protein received
time frame: 28 days
60 day mortality
time frame: 60 days

Secondary Outcomes

ICU mortality
time frame: 28 days
Development of ICU-acquired infections
time frame: 28 days
Hospital mortality
time frame: 60 days
Duration of ICU stay
time frame: 60 days
Multiple organ dysfunction (SOFA and PODS)
time frame: 28 days
Duration of mechanical ventilation
time frame: 28 days
time frame: 60 days
Duration of hospital stay
time frame: 60 days
Muscle Function - Ultrasounds
time frame: 28 days
Muscle Function - CT Scans
time frame: 28 days
Muscle Function - Hand-Grip Strength
time frame: ICU Discharge
Muscle Function - 6 min walk test
time frame: ICU Discharge

Eligibility Criteria

Male or female participants at least 18 years old.

Inclusion Criteria: - Critically ill adult patient (≥ 18 years) admitted to ICU - Has acute respiratory failure (ARF) i.e. expected to remain mechanically ventilated for more than 48 hours - Expected ICU dependency of 5 or more days - On or expected to initiate enteral nutrition within 7 days of ICU admission - BMI <25 or ≥ 35 based on pre-ICU actual or estimated dry weight Exclusion Criteria: - >72 hours from admission to ICU to time of consent - Not expected to survive an additional 48 hrs from screening evaluation - A lack of commitment to full aggressive care (anticipated withholding or withdrawing treatments in the first week but isolated DNR acceptable) - Patients already receiving PN at screening - Absence of All gastrointestinal risk factors, defined as: 1. High Apache II Score (>20) 2. On more than 1 vasopressor or increasing doses or vasopressors 3. Receiving continuous infusion of narcotics 4. High nasogastric/orogastric output (>500 mL over 24 hours) 5. Recent surgery involving esophagus, stomach, or small bowel OR peritoneal contamination with bowel contents 6. Pancreatitis 7. Multiple gastrointestinal investigations 8. Recent history of diarrhea/C. Difficile 9. Surgical patients with future surgeries planned 10. Ruptured or dissected abdominal aortic aneurysm - Patients admitted with diabetic ketoacidosis or non-ketotic hyperosmolar coma - Pregnant or lactating patients - Patients with clinical fulminant hepatic failure - Patients with Cirrhosis Child's Class C Liver Disease (except those on a transplant list or transplantable) - Dedicated port of central line not available - Known allergy to study nutrients (soy, eggs or olive products) - Enrolment in another industry sponsored ICU intervention study

Additional Information

Official title A Randomized Trial of Supplemental Parenteral Nutrition in Under and Over Weight Critically Ill Patients: The TOP UP Trial (Pilot)
Description Background Critically ill patients are often hypermetabolic and can rapidly become nutritionally compromised. Malnutrition is prevalent in these patients and has been associated with increased morbidity and mortality. Standard nutrition therapy, i.e. provision of calories, protein and other nutrients consists primarily of enteral nutrition (via a feeding tube into the gastrointestinal tract), parenteral nutrition (via an intravenous tube into the blood), or occasionally a combination of both. However, the provision of nutrition is sub-optimal and the majority of critically-ill patients do not meet nutritional requirements. Recent studies report that average energy intakes of critically ill patients are only 49% to 70% of calculated requirements. Despite repeated, sustained efforts over the past few years, the investigators have not significantly improved the amount of calories delivered via the enteral route. This leads us to conclude that if the investigators are to be successful at increasing the provision of calories and protein to patients at-risk, the investigators will have to supplement the calories via the parenteral route. Critically ill patients that are at extremes of weight are at a higher nutritional risk and have higher mortality rates. A recent International multicenter observational study of 2772 ICU patients from 165 ICUs showed a significant inverse linear relationship between the odds of mortality and total daily calories received. Increased amounts of calories was most important for the BMI < 20 group followed by the BMI 20 -< 25 group and BMI > 35 group with no benefit of increased calorie intake for patients in the BMI 25 -< 35 group. Feeding an additional 1000 kcals almost halved the odds of 60-day mortality in patients with a BMI < 25 or > 35. Similar results were observed for feeding an additional 30 grams of protein per day. Thus, a prospective randomized trial is warranted to confirm our hypothesis that in patients with a BMI of < 25 and those with a BMI > 35 increasing the provision of more energy and protein can impact clinical outcomes. The results of this study will serve to answer some fundamental questions with regards to impact of amount of energy and protein delivered to nutritional at-risk ICU patients and will inform current practice. Study Intervention: Patients will be randomized to one of 2 interventions: enteral nutrition alone or enteral nutrition plus parenteral nutrition (supplemental PN group).
Trial information was received from ClinicalTrials.gov and was last updated in March 2015.
Information provided to ClinicalTrials.gov by Clinical Evaluation Research Unit at Kingston General Hospital.